Over 20% of patients taking Nirmatrelvir-ritonavir therapy, commonly known as Paxlovid, suffer from the rebound, compared to less than the 2% chance seen in other treatment groups, a Harvard Medical School study revealed.

People with COPD are at high risk of developing heart disease, lung cancer and other complications, including depression and high blood pressure in the lung arteries.